1. The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: a population-based modelling study;Morgan;EClinicalMedicine,2022
2. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5—a population-based study;De Angelis;Lancet Oncol,2014
3. First-Line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial;Janjigian;J Clin Oncol,2024
4. KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial;Rha;Lancet Oncol,2023
5. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial;Qiu;BMJ,2024